Publications
2024
[1] Tseng, C. C.**, Ku, M. H.**, Wu, Y. W.**, Huang, W. L.**, Wu, W. M.**, Pai, C. H.**, and Chen, C. W. (2024) Therapeutic Options Targeting Ataxia-Telangiectasia Mutated (ATM) Mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer. Anticancer Research, 44(4):1353-1364. (**undergraduate author)
2023
[2] Liu, B.R., Chen, C. W., Huang, Y. W., and Lee, H. J. (2023) Cell-Penetrating Peptides for Use in Development of Transgenic Plants. Molecules, 28, 3367. https://doi.org/10.3390/molecules28083367
[3] Airik, M. Arbore, H. Childs, E. Huynh, A.B. Phua, Y.L. Chen, C.W. Aird, K. Bharathi, S. Zhang, B. Conlon, P. Kmoch, S. Kidd, K. Bleyer, A.J. Vockley, J. Goetzman, E. Wipf, P. and Airik, R. (2023) Mitochondrial ROS Triggers KIN Pathogenesis in FAN1-Deficient Kidneys. Antioxidants, 12, 900.
[4] Huang, Z.*, Chen, C. W.*, Buj, R., Tangudu, N. K., Fang, R. S., Leon, K. E., Dahl, E. S., Varner, E. L., von Krusenstiern, E., Cole, A. R., Snyder, N. W., and Aird, K. M. (2023) ATM inhibition drives metabolic adaptation via induction of macropinocytosis, J Cell Biol 222. (*Co-first author)
2022
[5] Wu, M. M., Chen, C. W., Chen, C. Y., Lee, C., H., Chou, M., Hsu, Y. I., Lee, T. C., and Chen, C. J. (2022) TIMP3 Gene Polymorphisms -1296 T>C and -915 A>G Increase Susceptibility to Arsenic-induced Skin Cancer: A Cohort Study and in Silico Analysis for Mutation Impact, Int J Mol Sci 23(23), 14980
[6] Chuang, H. W., Pan, J. H., Cai, Y. X., Rupa, D., Huang, T. S., Kuo, T. C., Lin, C. W., Chen, C. W., Lin, C. C., Lee, H. S., and Yuan, T. C. (2022) Reciprocal regulation of CIP2A and AR expression in prostate cancer cells, Discov Oncol 13, 87.
[7] Chen, C. W.*, Hsieh, M. J.*, Ju, P. C., Hsieh, Y. H., Su, C. W., Chen, Y. L., Yang, S. F., and Lin, C. W. (2022) Curcumin analog HO-3867 triggers apoptotic pathways through activating JNK1/2 signalling in human oral squamous cell carcinoma cells, J Cell Mol Med 26, 2273-2284. (*Co-first author)
[8] Chen, C. W. (2022) Comment on 'Long noncoding RNA UCA1 promotes glutamine-driven anaplerosis of bladder cancer by interacting with hnRNP I/L to upregulate GPT2 expression' by Chen et al.'", Transl Oncol 18, 101372.
2021
[9] Li, J., Zhang, Y., Sun, J., Chen, L., Gou, W., Chen, C. W., Zhou, Y., Li, Z., Chan, D. W., Huang, R., Pei, H., Zheng, W., Li, Y., Xia, M., and Zhu, W. (2021) Discovery and characterization of potent And-1 inhibitors for cancer treatment, Clin Transl Med 11, e627.
[10] Leon, K. E., Buj, R., Lesko, E., Dahl, E. S., Chen, C. W., Tangudu, N. K., Imamura-Kawasawa, Y., Kossenkov, A. V., Hobbs, R. P., and Aird, K. M. (2021) DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A, J Cell Biol 220(8):e202008101.
2020
[11] Chen, C. W., Buj, R., Dahl, E. S., Leon, K. E., and Aird, K. M. (2020) ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells, Heliyon 6, e05097.
[12] Kim, Y. S., Gupta Vallur, P., Jones, V. M., Worley, B. L., Shimko, S., Shin, D. H., Crawford, L. C., Chen, C. W., Aird, K. M., Abraham, T., Shepherd, T. G., Warrick, J. I., Lee, N. Y., Phaeton, R., Mythreye, K., and Hempel, N. (2020) Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells, Oncogene 39, 1619-1633.
2019
[13] Zhang, Y., Li, Z., Hao, Q., Tan, W., Sun, J., Li, J., Chen, C. W., Li, Z., Meng, Y., Zhou, Y., Han, Z., Pei, H., DePamphilis, M. L., and Zhu, W. (2019) The Cdk2-c-Myc-miR-571 Axis Regulates DNA Replication and Genomic Stability by Targeting Geminin, Cancer Res 79, 4896-4910.
[14] Li, Z., Zhou, W., Zhang, Y., Sun, W., Yung, M. M. H., Sun, J., Li, J., Chen, C. W., Li, Z., Meng, Y., Chai, J., Zhou, Y., Liu, S. S., Cheung, A. N. Y., Ngan, H. Y. S., Chan, D. W., Zheng, W., and Zhu, W. (2019) ERK Regulates HIF1alpha-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer, Clin Cancer Res 25, 5947-5960.
[15] Chen, C. W.*, Li, Y.*, Hu, S., Zhou, W., Meng, Y., Li, Z., Zhang, Y., Sun, J., Bo, Z., DePamphilis, M. L., Yen, Y., Han, Z., and Zhu, W. (2019) DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2), Oncogene 38, 2364-2379. (*Co-first author)
[16] Buj, R., Chen, C. W., Dahl, E. S., Leon, K. E., Kuskovsky, R., Maglakelidze, N., Navaratnarajah, M., Zhang, G., Doan, M. T., Jiang, H., Zaleski, M., Kutzler, L., Lacko, H., Lu, Y., Mills, G. B., Gowda, R., Robertson, G. P., Warrick, J. I., Herlyn, M., Imamura, Y., Kimball, S. R., DeGraff, D. J., Snyder, N. W., and Aird, K. M. (2019) Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming, Cell Rep 28, 1971-1980 e1978.
2018
[17] Zhou, W., Sun, W., Yung, M. M. H., Dai, S., Cai, Y., Chen, C. W., Meng, Y., Lee, J. B., Braisted, J. C., Xu, Y., Southall, N. T., Shinn, P., Huang, X., Song, Z., Chen, X., Kai, Y., Cai, X., Li, Z., Hao, Q., Cheung, A. N. Y., Ngan, H. Y. S., Liu, S. S., Barak, S., Hao, J., Dai, Z., Tzatsos, A., Peng, W., Pei, H., Han, Z., Chan, D. W., Zheng, W., and Zhu, W. (2018) Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance, Oncogene 37, 3981-3997.
[18] Meng, Y.*, Chen, C. W.*, Yung, M. M. H., Sun, W., Sun, J., Li, Z., Li, J., Li, Z., Zhou, W., Liu, S. S., Cheung, A. N. Y., Ngan, H. Y. S., Braisted, J. C., Kai, Y., Peng, W., Tzatsos, A., Li, Y., Dai, Z., Zheng, W., Chan, D. W., and Zhu, W. (2018) DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer, Cancer Lett 428, 104-116. (*Co-first author)
2016
[19] Lai, K. C., Liu, C. J., Lin, T. J., Mar, A. C., Wang, H. H., Chen, C. W., Hong, Z. X., and Lee, T. C. (2016) Blocking TNF-alpha inhibits angiogenesis and growth of IFIT2-depleted metastatic oral squamous cell carcinoma cells, Cancer Lett 370, 207-215.
[20] Chen, C. W., Wu, M. H., Chen, Y. F., Yen, T. Y., Lin, Y. W., Chao, S. H., Tala, S., Tsai, T. H., Su, T. L., and Lee, T. C. (2016) A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non-Small Cell Lung Cancer Cells, Neoplasia 18, 199-212.
2014
[21] Sanjiv, K., Chen, C. W., Kakadiya, R., Tala, S., Suman, S., Wu, M. H., Chen, Y. H., Su, T. L., and Lee, T. C. (2014) PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[alpha]indene Derivative in Lung Cancer Cells, Transl Oncol 7, 256-266 e255.
2013
[22] Chaniyara, R.*, Tala, S.*, Chen, C. W.*, Zang, X., Kakadiya, R., Lin, L. F., Chen, C. H., Chien, S. I., Chou, T. C., Tsai, T. H., Lee, T. C., Shah, A., and Su, T. L. (2013) Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition, J Med Chem 56, 1544-1563. (*Co-first author)
2012
[23] Chaniyara, R., Tala, S., Chen, C. W., Lee, P. C., Kakadiya, R., Dong, H., Marvania, B., Chen, C. H., Chou, T. C., Lee, T. C., Shah, A., and Su, T. L. (2012) Synthesis and antitumor evaluation of novel benzo[d]pyrrolo[2,1-b]thiazole derivatives, Eur J Med Chem 53, 28-40.
2024
[1] Tseng, C. C.**, Ku, M. H.**, Wu, Y. W.**, Huang, W. L.**, Wu, W. M.**, Pai, C. H.**, and Chen, C. W. (2024) Therapeutic Options Targeting Ataxia-Telangiectasia Mutated (ATM) Mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer. Anticancer Research, 44(4):1353-1364. (**undergraduate author)
2023
[2] Liu, B.R., Chen, C. W., Huang, Y. W., and Lee, H. J. (2023) Cell-Penetrating Peptides for Use in Development of Transgenic Plants. Molecules, 28, 3367. https://doi.org/10.3390/molecules28083367
[3] Airik, M. Arbore, H. Childs, E. Huynh, A.B. Phua, Y.L. Chen, C.W. Aird, K. Bharathi, S. Zhang, B. Conlon, P. Kmoch, S. Kidd, K. Bleyer, A.J. Vockley, J. Goetzman, E. Wipf, P. and Airik, R. (2023) Mitochondrial ROS Triggers KIN Pathogenesis in FAN1-Deficient Kidneys. Antioxidants, 12, 900.
[4] Huang, Z.*, Chen, C. W.*, Buj, R., Tangudu, N. K., Fang, R. S., Leon, K. E., Dahl, E. S., Varner, E. L., von Krusenstiern, E., Cole, A. R., Snyder, N. W., and Aird, K. M. (2023) ATM inhibition drives metabolic adaptation via induction of macropinocytosis, J Cell Biol 222. (*Co-first author)
2022
[5] Wu, M. M., Chen, C. W., Chen, C. Y., Lee, C., H., Chou, M., Hsu, Y. I., Lee, T. C., and Chen, C. J. (2022) TIMP3 Gene Polymorphisms -1296 T>C and -915 A>G Increase Susceptibility to Arsenic-induced Skin Cancer: A Cohort Study and in Silico Analysis for Mutation Impact, Int J Mol Sci 23(23), 14980
[6] Chuang, H. W., Pan, J. H., Cai, Y. X., Rupa, D., Huang, T. S., Kuo, T. C., Lin, C. W., Chen, C. W., Lin, C. C., Lee, H. S., and Yuan, T. C. (2022) Reciprocal regulation of CIP2A and AR expression in prostate cancer cells, Discov Oncol 13, 87.
[7] Chen, C. W.*, Hsieh, M. J.*, Ju, P. C., Hsieh, Y. H., Su, C. W., Chen, Y. L., Yang, S. F., and Lin, C. W. (2022) Curcumin analog HO-3867 triggers apoptotic pathways through activating JNK1/2 signalling in human oral squamous cell carcinoma cells, J Cell Mol Med 26, 2273-2284. (*Co-first author)
[8] Chen, C. W. (2022) Comment on 'Long noncoding RNA UCA1 promotes glutamine-driven anaplerosis of bladder cancer by interacting with hnRNP I/L to upregulate GPT2 expression' by Chen et al.'", Transl Oncol 18, 101372.
2021
[9] Li, J., Zhang, Y., Sun, J., Chen, L., Gou, W., Chen, C. W., Zhou, Y., Li, Z., Chan, D. W., Huang, R., Pei, H., Zheng, W., Li, Y., Xia, M., and Zhu, W. (2021) Discovery and characterization of potent And-1 inhibitors for cancer treatment, Clin Transl Med 11, e627.
[10] Leon, K. E., Buj, R., Lesko, E., Dahl, E. S., Chen, C. W., Tangudu, N. K., Imamura-Kawasawa, Y., Kossenkov, A. V., Hobbs, R. P., and Aird, K. M. (2021) DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A, J Cell Biol 220(8):e202008101.
2020
[11] Chen, C. W., Buj, R., Dahl, E. S., Leon, K. E., and Aird, K. M. (2020) ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells, Heliyon 6, e05097.
[12] Kim, Y. S., Gupta Vallur, P., Jones, V. M., Worley, B. L., Shimko, S., Shin, D. H., Crawford, L. C., Chen, C. W., Aird, K. M., Abraham, T., Shepherd, T. G., Warrick, J. I., Lee, N. Y., Phaeton, R., Mythreye, K., and Hempel, N. (2020) Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells, Oncogene 39, 1619-1633.
2019
[13] Zhang, Y., Li, Z., Hao, Q., Tan, W., Sun, J., Li, J., Chen, C. W., Li, Z., Meng, Y., Zhou, Y., Han, Z., Pei, H., DePamphilis, M. L., and Zhu, W. (2019) The Cdk2-c-Myc-miR-571 Axis Regulates DNA Replication and Genomic Stability by Targeting Geminin, Cancer Res 79, 4896-4910.
[14] Li, Z., Zhou, W., Zhang, Y., Sun, W., Yung, M. M. H., Sun, J., Li, J., Chen, C. W., Li, Z., Meng, Y., Chai, J., Zhou, Y., Liu, S. S., Cheung, A. N. Y., Ngan, H. Y. S., Chan, D. W., Zheng, W., and Zhu, W. (2019) ERK Regulates HIF1alpha-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer, Clin Cancer Res 25, 5947-5960.
[15] Chen, C. W.*, Li, Y.*, Hu, S., Zhou, W., Meng, Y., Li, Z., Zhang, Y., Sun, J., Bo, Z., DePamphilis, M. L., Yen, Y., Han, Z., and Zhu, W. (2019) DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2), Oncogene 38, 2364-2379. (*Co-first author)
[16] Buj, R., Chen, C. W., Dahl, E. S., Leon, K. E., Kuskovsky, R., Maglakelidze, N., Navaratnarajah, M., Zhang, G., Doan, M. T., Jiang, H., Zaleski, M., Kutzler, L., Lacko, H., Lu, Y., Mills, G. B., Gowda, R., Robertson, G. P., Warrick, J. I., Herlyn, M., Imamura, Y., Kimball, S. R., DeGraff, D. J., Snyder, N. W., and Aird, K. M. (2019) Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming, Cell Rep 28, 1971-1980 e1978.
2018
[17] Zhou, W., Sun, W., Yung, M. M. H., Dai, S., Cai, Y., Chen, C. W., Meng, Y., Lee, J. B., Braisted, J. C., Xu, Y., Southall, N. T., Shinn, P., Huang, X., Song, Z., Chen, X., Kai, Y., Cai, X., Li, Z., Hao, Q., Cheung, A. N. Y., Ngan, H. Y. S., Liu, S. S., Barak, S., Hao, J., Dai, Z., Tzatsos, A., Peng, W., Pei, H., Han, Z., Chan, D. W., Zheng, W., and Zhu, W. (2018) Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance, Oncogene 37, 3981-3997.
[18] Meng, Y.*, Chen, C. W.*, Yung, M. M. H., Sun, W., Sun, J., Li, Z., Li, J., Li, Z., Zhou, W., Liu, S. S., Cheung, A. N. Y., Ngan, H. Y. S., Braisted, J. C., Kai, Y., Peng, W., Tzatsos, A., Li, Y., Dai, Z., Zheng, W., Chan, D. W., and Zhu, W. (2018) DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer, Cancer Lett 428, 104-116. (*Co-first author)
2016
[19] Lai, K. C., Liu, C. J., Lin, T. J., Mar, A. C., Wang, H. H., Chen, C. W., Hong, Z. X., and Lee, T. C. (2016) Blocking TNF-alpha inhibits angiogenesis and growth of IFIT2-depleted metastatic oral squamous cell carcinoma cells, Cancer Lett 370, 207-215.
[20] Chen, C. W., Wu, M. H., Chen, Y. F., Yen, T. Y., Lin, Y. W., Chao, S. H., Tala, S., Tsai, T. H., Su, T. L., and Lee, T. C. (2016) A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non-Small Cell Lung Cancer Cells, Neoplasia 18, 199-212.
2014
[21] Sanjiv, K., Chen, C. W., Kakadiya, R., Tala, S., Suman, S., Wu, M. H., Chen, Y. H., Su, T. L., and Lee, T. C. (2014) PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[alpha]indene Derivative in Lung Cancer Cells, Transl Oncol 7, 256-266 e255.
2013
[22] Chaniyara, R.*, Tala, S.*, Chen, C. W.*, Zang, X., Kakadiya, R., Lin, L. F., Chen, C. H., Chien, S. I., Chou, T. C., Tsai, T. H., Lee, T. C., Shah, A., and Su, T. L. (2013) Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition, J Med Chem 56, 1544-1563. (*Co-first author)
2012
[23] Chaniyara, R., Tala, S., Chen, C. W., Lee, P. C., Kakadiya, R., Dong, H., Marvania, B., Chen, C. H., Chou, T. C., Lee, T. C., Shah, A., and Su, T. L. (2012) Synthesis and antitumor evaluation of novel benzo[d]pyrrolo[2,1-b]thiazole derivatives, Eur J Med Chem 53, 28-40.
Selected research presentations
Oral Presentations
[1] Chen, C. W. 2023. A Flipped Classroom Using Multiple Information Technology to Strengthen Independent Learning, 2023 Academic Symposium: Educational Innovation and Sustainable Development, Tamkang University, Taipei, Taiwan.
[2] Chen, C. W. 2023. Impact of Flipped Classroom on Learning in Life Sciences, The 10th Hwashan Conference on Education, Hualien, Taiwan.
[3] Chen, C. W. 2022. Targeting DNA for anticancer treatments, Mu-Shan Seminar, Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan (Online webinar).
Poster Presentations
[1] Chen, C. W., (2023) RRM2 inhibition synergizes with PARP inhibitor in ovarian cancer cells. AACR Annual Meeting 2023, Orlando, FL, USA.
[2] Chen, C. W. (2022) Novel RRM2 inhibitor Osalmid arguments PARPi potency against ovarian cancer. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.
[3] Tseng, T. C. and Chen, C. W., (2022) Novel p53 inhibitor HO-3867 augments the anticancer effect of PARP inhibitor in ovarian cancer. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.
[4] Huang, W. L. and Chen, C. W., (2022) Development of synthetic lethality targeting genome integrity for treatment of ovarian cancer. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.
[5] Wu, Y. C. and Chen, C. W., (2022) Exploring the relationship and regulation of CACFD1 and cell metabolism in ovarian cancer cell competition. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.
[6] Ku, M. H. and Chen, C. W., (2022) Investigation of the synergistic inhibition of the proliferation of human epithelial ovarian cancer cells by combined novel antitumor drugs BO-1978 and HO-3867. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.
Oral Presentations
[1] Chen, C. W. 2023. A Flipped Classroom Using Multiple Information Technology to Strengthen Independent Learning, 2023 Academic Symposium: Educational Innovation and Sustainable Development, Tamkang University, Taipei, Taiwan.
[2] Chen, C. W. 2023. Impact of Flipped Classroom on Learning in Life Sciences, The 10th Hwashan Conference on Education, Hualien, Taiwan.
[3] Chen, C. W. 2022. Targeting DNA for anticancer treatments, Mu-Shan Seminar, Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan (Online webinar).
Poster Presentations
[1] Chen, C. W., (2023) RRM2 inhibition synergizes with PARP inhibitor in ovarian cancer cells. AACR Annual Meeting 2023, Orlando, FL, USA.
[2] Chen, C. W. (2022) Novel RRM2 inhibitor Osalmid arguments PARPi potency against ovarian cancer. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.
[3] Tseng, T. C. and Chen, C. W., (2022) Novel p53 inhibitor HO-3867 augments the anticancer effect of PARP inhibitor in ovarian cancer. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.
[4] Huang, W. L. and Chen, C. W., (2022) Development of synthetic lethality targeting genome integrity for treatment of ovarian cancer. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.
[5] Wu, Y. C. and Chen, C. W., (2022) Exploring the relationship and regulation of CACFD1 and cell metabolism in ovarian cancer cell competition. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.
[6] Ku, M. H. and Chen, C. W., (2022) Investigation of the synergistic inhibition of the proliferation of human epithelial ovarian cancer cells by combined novel antitumor drugs BO-1978 and HO-3867. 2022 Eastern Biotechnology and Biomedical Symposium, Hualien, Taiwan.